On May 6, 2026, CellCentric, a clinical-stage biotechnology company developing inobrodib—a first-in-class oral p300/CBP inhibitor for multiple myeloma—announced the completion of a $220 million oversubscribed Series D financing. Led by Venrock Healthcare Capital Partners with participation from Fidelity, Sofinova Partners, HBM Healthcare, and existing investors including RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and BrightEdge of the American Cancer Society, the funding will support pivotal clinical development of inobrodib, including the ongoing Phase 2 DOMMINO-1 trial in the UK and US and the planned global Phase 3 DOMMINO-2 trial in the second half of 2026. The proceeds will also expand inobrodib’s evaluation in combination and maintenance settings. Inobrodib, combined with pomalidomide and dexamethasone (InoPd), demonstrated a doubling of response rates versus historical controls in heavily pretreated relapsed/refractory multiple myeloma patients (median five prior lines) at the 20 mg dose in Phase 2 data presented at ASH 2025. With cash runway extending to 2029, CellCentric is considering an IPO in 2027 while also exploring strategic acquisition opportunities.

On May 1, 2026, the U.S. FDA approved Veppanu (vepdegestrant), a first-in-class oral PROTAC estrogen receptor degrader developed by Arvinas and Pfizer, for adult patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed following at least one line of endocrine therapy. The approval is based on results from the Phase III VERITAC-2 trial (NCT05654623), which enrolled 624 patients, including 270 with ESR1 mutations. In the ESR1-mutant subgroup, vepdegestrant demonstrated a statistically significant improvement in progression-free survival (median PFS: 5.0 months vs. 2.1 months with fulvestrant; HR=0.57, p=0.0001). The overall population showed a modest PFS benefit (3.7 vs. 3.6 months; HR=0.83, p=0.0358). Common grade ≥3 adverse events included fatigue (26.6%), elevated ALT (14.4%), AST (14.4%), and nausea (13.5%); treatment discontinuation due to adverse events occurred in 2.9% of patients. Overall survival data remain immature.

On April 28, 2026, Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd., resolving patent litigation in the U.S. District Court for the District of Delaware concerning VYNDAMAX® (tafamidis), a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). The settlements extend VYNDAMAX’s effective U.S. patent protection to June 1, 2031, supporting stable revenue expectations through mid-2031. VYNDAMAX remains the leading ATTR-CM therapy in the U.S., with a 75% prescription share, offering once-daily oral dosing and proven clinical benefits including reduced all-cause mortality and cardiovascular hospitalizations. Pfizer discontinued VYNDAQEL in the U.S. as of December 31, 2025, consolidating treatment under the more patient-friendly VYNDAMAX formulation.

Li Caihui, Head of Intellectual Property at Junshi Biosciences, will deliver a keynote speech titled 'Out-Licensing-Oriented Patent Strategy: A Case Study of Pfizer–3SBio Bispecific Antibody SSGJ-707' at the IP Forum of the 2026 CBA-China Annual Conference in Wuxi. The presentation will analyze the global patent layout and licensing framework behind SSGJ-707, a PD-1/VEGF bispecific antibody developed by 3SBio and licensed to Pfizer for ex-China territories, highlighting strategic considerations for maximizing international commercial value through IP design.

Pfizer's ecnoglutide, a GLP-1 receptor agonist for weight management licensed from Chinese biotech Sciwind, has launched in pre-sale on JD.com at ¥489 per 1.2ml pen, with shipments starting April 27, 2026. This move signals a pivotal shift in China’s anti-obesity drug market—from R&D and regulatory milestones to real-world commercial execution. With established sales benchmarks from Novo Nordisk’s Wegovy (¥260M in 2025) and Innovent’s Xinermei (¥416M), the competition now hinges on channel efficiency, patient conversion, retention, and unit economics. Pfizer’s rapid go-to-market via license-in underscores a new paradigm where global pharma leverages local assets not just for molecules, but for speed-to-revenue. As China formalizes obesity care through national guidelines, the true test for players is no longer who gets approved first, but who can build sustainable, cash-flow-positive commercial operations.

This systematic review and meta-analysis synthesizes real-world evidence from 36 studies across nine countries, involving 121.8 million individuals during the 2023/24 to 2024/25 RSV seasons, to evaluate the uptake, effectiveness, and safety of three approved RSV vaccines for older adults—GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mRESVIA. While vaccine effectiveness is high and overall safety favorable, a slight increased risk of Guillain-Barré syndrome (GBS) was observed, warranting continued long-term surveillance.

On January 20, Pfizer announced a licensing agreement with Novavax granting Pfizer full control over the development, manufacturing, and commercialization of all vaccine products containing Novavax’s Matrix-M adjuvant, excluding distribution and supply. Novavax will receive a $30 million upfront payment in Q1 2026 and is eligible for up to $500 million in milestone payments. The deal comes as Novavax faces declining demand for its Nuvaxovid COVID-19 vaccine and mounting investor pressure amid widening net losses.

Pfizer, Merck, Eli Lilly, Novartis, AstraZeneca, Vertex, and Amgen have jointly published a comprehensive white paper addressing solvent sustainability in early-stage drug discovery. Based on an analysis of over 400,000 medicinal chemistry reactions from 2000 to 2021, the report highlights that solvents account for 80–90% of pharmaceutical waste mass and 75–80% of lifecycle environmental impact. It identifies widespread use of hazardous solvents—such as DCM, DMF, 1,4-dioxane, and hexane—in more than 40% of reactions and proposes green alternatives for common transformations like amide coupling and Suzuki-Miyaura reactions. The white paper also advocates for miniaturization and high-throughput experimentation (HTE) to drastically reduce solvent consumption, alongside practical tools like the CHEM21 and ACS-GCIPR solvent selection guides to support sustainable decision-making across the drug discovery pipeline.

On November 13, Pfizer announced the successful completion of its acquisition of Metsera, a clinical-stage biopharmaceutical company focused on next-generation therapies for obesity and cardiometabolic diseases. Pfizer acquired all outstanding shares of Metsera at $65.60 per share in cash, representing an enterprise value of approximately $7 billion, plus contingent value rights (CVRs) of up to $20.65 per share tied to three clinical and regulatory milestones, bringing the total deal value to around $9.2 billion. Metsera’s pipeline now integrated into Pfizer includes MET-097i (a once-weekly or once-monthly GLP-1 receptor agonist advancing toward Phase III), MET-233i (a once-monthly amylin analog in Phase I as monotherapy and in combination with MET-097i), oral GLP-1 receptor agonists in Phase I, and preclinical nutrient-stimulated hormone (NuSH) therapies. The acquisition positions Pfizer to accelerate innovation in one of medicine’s fastest-growing therapeutic areas.

As one of the most popular sections in previous CIIEs, the Medical Equipment and Healthcare Products exhibition area moved to Halls 1.1, 1.2, and 2.2 this year. The world’s top ten medical device giants and 12 Fortune Global 500 pharmaceutical companies gathered in this expansive space exceeding 70,000 square meters.